Securities Times reporter Mao Kexin

　　The growth in demand for new crown antigen testing was fully reflected in the quarterly report, and the performance of many manufacturers broke the table.

On the evening of April 24, Wanfu Bio (300482) released its first quarterly report. The company achieved operating income of 2.625 billion yuan, a year-on-year increase of 276.87%; net profit attributable to the parent was 904 million yuan, a year-on-year increase of 481.32%.

　　The annual report disclosed by Wanfu Bio at the same time shows that in 2021, the operating income will be 3.361 billion yuan, a year-on-year increase of 19.57%; the net profit attributable to the parent is 634 million yuan, a year-on-year increase of 0.04%.

Wanfu Biological plans to distribute a cash dividend of 3 yuan for every 10 shares.

　　In contrast, Wanfu Bio's revenue in the first quarter of this year has been equivalent to nearly 80% of the full year of 2021, and the net profit attributable to the parent in the first quarter has exceeded that of the whole of last year.

　　The high performance in the first quarter was mainly due to the contribution of the new crown testing business.

Wanfu Bio said that since the outbreak of the new crown pneumonia in Hong Kong in early 2022, the company has actively contributed to the prevention and control of the new crown epidemic in Hong Kong, and has done its best to provide new crown testing reagents, and the revenue of new crown testing products has increased significantly.

　　In March, antigen testing was recognized as a supplementary method for new crown screening. In addition, the repeated epidemics in various places have increased market demand.

Wanfu Bio said that, as one of the first companies in China to obtain the change of the registration certificate of the new crown antigen product, under the decision-making, deployment and overall coordination of the state, the company has made every effort to ensure the supply and serve the needs of national epidemic prevention and anti-epidemic, and effectively, orderly and effectively. Expand production and capacity, ensure supply scientifically, and provide support for epidemic prevention and control with rapid detection technology.

　　Up to now, Wanfu Bio's new crown antigen self-test products have passed the EU CE certification, and obtained the new crown antigen self-test certificates of Brazil, Russia, Australia, Thailand, Malaysia, Myanmar and other countries.

The company's new crown series detection reagent sales have covered more than 100 countries and regions in Europe, Asia, Latin America, and the Middle East.

　　In 2021, the sales revenue of the four product lines of Wanfu Bio's conventional business will be approximately 1.916 billion yuan, a year-on-year increase of 38.18%.

The sales revenue of new crown detection reagents was 1.145 billion yuan, a year-on-year increase of 9.61%.

At the same time, various expenses have also increased significantly. Among them, research and development expenses have increased by 39.96% year-on-year. Projects such as employee equity incentives and convertible bond financing have also increased management expenses and financial expenses by 40.81% and 74.9% respectively.

　　In addition to Wanfu Bio, a number of antigen detection reagent manufacturers performed "outrageous performances" in the first quarter.

Mingde Bio expects a net profit of 1.350 billion yuan to 1.450 billion yuan in the first quarter of this year, with a year-on-year increase of 295.61% to 324.91% in net profit; Aotai Bio is expected to make a profit of 1.03 billion yuan to 1.19 billion yuan in the first quarter, a year-on-year increase of 585% to 692%; nine An Medical is expected to make a profit of 14 billion to 16 billion yuan in the first quarter, a year-on-year increase of 367 to 420 times.

　　Jiu’an Medical disclosed on the evening of April 24 that the contracts and orders for the new crown antigen kits between its US subsidiary and New York and Massachusetts have been fulfilled.

Among them, the purchase order in New York state has not been completed. The original order was 185 million US dollars, which was later adjusted to 175 million US dollars; the Massachusetts state order has completed its delivery obligation and received 149 million US dollars in payment (the actual freight rate has increased) .

The two orders amounted to a total of about 2.1 billion yuan.